Statement from Ameridose

WESTBOROUGH, Mass.--(BUSINESS WIRE)--The following is a statement from Ameridose:

“Ameridose today agreed to voluntarily and temporarily cease certain operations, including production and shipping of all products, while the Massachusetts Department of Public Health, the Board of Registration in Pharmacy and the U.S. Food and Drug Administration conduct a targeted onsite inspection. This action was taken proactively and cooperatively with the Board of Registration of Pharmacy, out of an abundance of caution, to ensure the safety of all Ameridose products.

As part of this agreement, Mr. Barry Cadden has agreed to resign all corporate positions at Ameridose. Mr. Cadden has not been pharmacist in charge nor has he had any day to day role at Ameridose.

As the DPH stated earlier today, there is no indication at all of any contamination in any Ameridose products, and there has been no suggestion that medical professionals refrain from using any Ameridose products in circulation.

Ameridose voluntarily agreed to cease certain operations effective at 3 p.m. on October 10, for a period ending October 22. The agreement is subject to early termination or extension by mutual consent of Ameridose and the Board of Registration in Pharmacy.”